From: Gene modification strategies for next-generation CAR T cells against solid cancers
Costimulatory molecules | Functional characteristics | CAR target antigen | Malignancy | Clinical trials | Phase | Status | Enrolled patients | Sponsor |
---|---|---|---|---|---|---|---|---|
CD28 | Increased cytokine production; more potent effector function; more rapid T cell proliferation and tumor elimination [43] | Lewis Y | Advanced solid cancer | NCT03851146 | I | Recruiting | 30 | Peter MacCallum Cancer Centre |
Chlorotoxin | Glioma | NCT04214392 | I | Recruiting | 36 | City of Hope Medical Center | ||
HER2 | Sarcoma | NCT00902044 | I | Active, not recruiting | 36 | Baylor College of Medicine | ||
 | Glioblastoma | NCT01109095 | I | Completed | 16 | Baylor College of Medicine | ||
4-1BB | Greater persistence; increased central memory T cell generation [43] | PSCA | Prostate cancer | NCT03873805 | I | Recruiting | 33 | City of Hope Medical Center |
PD-L1 | Lung cancer | NCT03330834 | I | Recruiting | 22 | Sun Yat-sen University | ||
Mesothelin | Pancreatic cancer | NCT03638193 | I | Recruiting | 10 | Shenzhen BinDeBio Ltd. | ||
 | MPM | NCT01355965 | I | Completed | 18 | University of Pennsylvania | ||
 | Ovarian cancer | NCT02159716 | I | Completed | 19 | University of Pennsylvania | ||
GPC3 | Hepatocellular cancer | NCT02715362 | I/II | Recruiting | 30 | Shanghai GeneChem Co Ltd. | ||
IL13Ralpha2 | Melanoma | NCT04119024 | I | Recruiting | 24 | Jonsson Comprehensive Cancer Center | ||
 | Glioblastoma | NCT04003649 | I | Recruiting | 60 | City of Hope Medical Center | ||
CEA | Liver metastases | NCT02862704 | I/II | Recruiting | 20 | Xijing Hospital | ||
CD171 | Neuroblastoma | NCT02311621 | I | Recruiting | 40 | Seattle Children’s Hospital | ||
MET | Melanoma | NCT03060356 | I | Terminated | 77 | University of Pennsylvania | ||
 | Breast cancer | NCT03060356 | I | Terminated | 77 | University of Pennsylvania | ||
EGFRvIII | Glioblastoma | NCT03726515 | I | Active, not recruiting | 7 | University of Pennsylvania | ||
CD28 and 4-1BB | Strong PI3Kinase/Akt activation; reduced apoptosis of CD8+ T cells; enhanced effector function of CD8+ T cells [46] | CD171 | Neuroblastoma | NCT02311621 | I | Recruiting | 40 | Seattle Children's Hospital |
CD28 and OX40 | CD28-OX40-CD3ζ CAR increased the production of IL-2 and IL-10; CD28-CD3ζ-OX40 CAR decreased the production of IL-2 and IL-10 [39, 47] | GD2 | Neuroblastoma | NCT01822652 | I | Active, not recruiting | 11 | Baylor College of Medicine |
Sarcoma | NCT01953900 | I | Active, not recruiting | 26 | Baylor College of Medicine |